Figure 12. A meta-analysis of cardiovascular events in randomized testosterone trials. In this meta-analysis of cardiovascular-related events in randomized testosterone trials included from 91 eligible trials in the analysis of major adverse cardiovascular events (MACE). Compared with placebo, exogenous testosterone treatment did not show any significant increase in risk of MACE occurrence (odds ratio [OR] 0.97; 95% CI, 0.64 to 1.46). Figure reproduced with permission from Corona et al. J Sex Med. 2018 Jun;15(6):820-838.